Search PubMed⌕ Search

Biomedical subjects

B Muller

Publications and source records attributed to B Muller.

77 records · Page 5Linked to original sources

Role of endothelial nitric oxide in the response to angiotensin II of small mesenteric arteries of the rat.

The role of endothelium-derived nitric oxide (NO) in the vascular contractile response to angiotensin II (Ang II) has been investigated in isolated small mesenteric resistance arteries of the rat. Both contraction and intracellular Ca2+ ion concentration ([Ca2+]i) were monitored in vessels, with and without functional endothelium, which were exposed to physiological salt solution containing 25 mM KCl. Ang II induced concentration-dependent contractile responses and increases in [Ca2+]i which, at the concentration giving the maximal response (10 nM), were not sustained in arteries with functional endothelium; however, the presence of a functional endothelium did not modify the peak responses. Ang II did not increase the cyclic guanosine 3',5'-monophosphate content of the tissue nor did it induce relaxation in arteries precontracted with 3 microM noradrenaline. The decline of the Ang II responses was suppressed by removal of the endothelium or by exposure of arteries with endothelium to either the NO synthase inhibitor, N(omega)-nitro-L-arginine methyl ester (300 microM), or the cyclic GMP-dependent protein kinase inhibitor, Rp-8-bromoguanosine 3',5'-cyclic monophosphorothioate (30 microM). On the other hand, the NO donor SIN-1 (3-morpholino-sydnonimine, 10 microM) accelerated the decline in [Ca2+]i and contraction. These results show that endothelium-derived NO does not affect the magnitude of the phasic element of the response to Ang II, but is involved in the rapid attenuation of the tonic component. Activation of cyclic GMP-dependent protein kinase accounts for this effect of endothelium-derived NO.

Acetylcholine↗

[Nitric oxide storage in the cardiovascular system].

Nitric oxide (NO) is a highly reactive substance with short lifetime. In conditions of a living organism NO can be bound by the complexes used for transport and intracellular storage of NO. The main biological forms of NO store include S-nitrosothiols and dinitrosyl iron complexes capable of interconversion. The NO store formed by these complexes in the vascular wall, on the one hand, provides for protection from excessive free NO after its overproduction and, on the other hand, can be an additional NO source when it is deficient. Apparently, the efficiency of NO storage is genetically determined and corresponds to the inherited level of NO production in the organism. Controlled modulation of formation and dissociation of the NO store is a promising trend for further investigation.

Animals↗

[Efficacy of O-(beta-hydroxyethyl)-rutosides in the treatment of venous leg ulcers].

In a prospective 6 weeks study, done in 3 phlebology practices on 107 patients presenting an acute leg ulcer, we compared the efficacy of a combination of compression and HR (O-(Beta-hydroxyethyl)-rutosides with compression alone, based on objective and subjective parameters. These objective and subjective parameters are improved in both groups. A statistically significant superiority of the therapeutic combination is demonstrated in the cure of ulcers.

Bandages↗

[The DA240-4 discrete biochemical autoanalyser].

The principle of operation, design and main technical characteristics are described of a discrete biochemical autoanalyzer DA240-4 jointly elaborated by the USSR and GDR. This unit can be employed in big biochemical laboratories and in prophylactic institutions.

Autoanalysis↗

Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis.

OBJECTIVE: To evaluate the effect of 1.1% amino acid dialysate (AAD) (Nutrineal, Baxter, Castlebar, Ireland) on lipid metabolism in hyperlipidemic patients on continuous ambulatory peritoneal dialysis (CAPD). DESIGN: Patients were alternately assigned to receive AAD in the first (group A), or the second (group B), 6 months of a prospective cross-over study. SETTING: University teaching hospital. PATIENTS: Eighteen stable CAPD patients with a serum cholesterol 5.5 mmol/L or greater. INTERVENTIONS: One post prandial exchange of AAD during a 24-hour period for 6 months. MAIN OUTCOME MEASURES: A significant change in serum lipid levels. RESULTS: Patients in group A (n = 10) received a single daily exchange of AAD in place of their post prandial dextrose exchange for the first 6 months, and then crossed over to the dextrose phase. Patients in group B (n = 8) continued their usual dextrose dialysis for the first 6 months and then crossed over to receive AAD in the latter 6 months. Measurements of serum lipids and lipoproteins along with other biochemical parameters were made at regular intervals. Although a downward trend in mean serum total cholesterol was seen on AAD in group A, no significant change in total cholesterol, low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol was observed in any group. Mean serum triglycerides fell on AAD in both groups, but were not statistically significant. Serum lipoprotein(a) [Lp(a)] and apolipoprotein B were elevated in both groups but did not change on AAD or with time. No change was observed in serum apoprotein A1 levels. Serum Lp(a) was not correlated to dialysate protein excretion. No change in mean serum albumin was observed, in either group, on AAD. KT/V urea, total weekly creatinine clearance, net ultrafiltration, and dialysate protein excretion remained unchanged on AAD. CONCLUSIONS: The use of AAD, although clinically safe and without side effects, had no effect on the dyslipidemia in our group of CAPD patients.

Adult↗